Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Lanham, Maryland Clinical Trials

A listing of Lanham, Maryland clinical trials actively recruiting patient volunteers.

RESULTS

Found (5) clinical trials

A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma

This is a trial of TTI-622 in subjects with relapsed or refractory lymphoma or myeloma. TTI-622 (SIRP-IgG4 Fc), is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRP with the Fc domain of human immunoglobulin (IgG4). TTI-622 acts by ...

Phase

8.44 miles

Learn More »

The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors. The main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of ...

Phase

8.44 miles

Learn More »

A Study to Assess Safety Tolerability Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)

The purpose of this study is to explore the safety, preliminary clinical benefit, and activity of BIVV009 in patients with chronic immune thrombocytopenia.

Phase

8.44 miles

Learn More »

Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies

This is a multi-institutional Phase I dose-escalation and dose-expansion trial for patients with advanced, solid tumor malignancies who have pre-identified deleterious germline or somatic mutations in the homologous recombination deoxyribonucleic acid (DNA) repair pathway (HR deficient). The trial is designed to assess the efficacy and safety of niraparib plus carboplatin ...

Phase

8.44 miles

Learn More »

HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals

Treatment Description: This is a phase I, multi-site, study of the safety, immunologic and virologic responses of ex vivo expanded HIV-1 multi-antigen specific T-cell therapy (HST-NEET) as a therapeutic strategy in HIV-infected individuals suppressed on ART. Patients will be screened for eligibility in Step 1 and undergo a blood draw ...

Phase

9.68 miles

Learn More »